abi-011
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01163071)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Topoisomerase IINHIBITOR
Topoisomerase I inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- abi-011
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02582827 | Phase 1 | Aug 1, 2017 | NantWorks |
| NCT01163071 | Phase 1 | Mar 1, 2011 | Celgene, University of Texas, San Antonio, Wayne State University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 1 | 1 | 1 | 2011 |
| NantWorks | For profit | 1 | 1 | 1 | 2017 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Wayne State University | Academic/Hospital | 1 | 0 | 1 | 2011 |
4 organizations
Page 1 / 1